Deal with GE boosts Fischer results

Article

A $6.2 million windfall from the sale of its Tilt-C technology to GE Medical Systems helped Fischer Imaging of Denver land solidly in the black for its first quarter (end-April). The company also reported a 3.6% increase in product sales for the quarter

A $6.2 million windfall from the sale of its Tilt-C technology to GE Medical Systems helped Fischer Imaging of Denver land solidly in the black for its first quarter (end-April). The company also reported a 3.6% increase in product sales for the quarter on higher service revenue and increased mammography shipments.

Fischer posted revenues of $20.4 million, compared with sales of $13.7 million in the first quarter of 1998. Excluding the GE payment, Fischer would have posted sales of $14.2 million. Fischer in April agreed to sell manufacturing rights to Tilt-C to Milwaukee-based GE (SCAN 4/14/99).

On the profit side, Fischer recorded net income of $3.4 million, compared with a net loss of $1.1 million in the same period a year ago. The company posted an operating loss of $1.6 million for the quarter, due in large part to costs associated with the move of its manufacturing operations from Addison, IL, to Denver.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.